Ruxolitinib to prevent acute GVHD after stem cell transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests whether starting ruxolitinib early, guided by a blood marker, can prevent acute graft-versus-host disease (aGVHD) after a stem cell transplant. It's for people who have already had a transplant and are at risk for this complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell transplant from any donor or stem cell source.
- You received a specific GVHD prevention combo: a calcineurin inhibitor plus post transplant cyclophosphamide.
- You do not have acute GVHD yet at the start of the study drug.
- You are not pregnant, on dialysis, or needing a ventilator or high oxygen.
- You have normal liver function tests (bilirubin and enzymes within certain limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests whether adding stem cells (remestemcel-L) to ruxolitinib—a medication that helps control the immune system—can help treat severe graft-versus-host disease (GVHD) that hasn't responded to steroids. GVHD is a complication after bone marrow or stem cell transplant where the new immune cells attack your body.
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Hear when a new GVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.